Loading
Sentiment · FY2026 Q2
As of FY2026 Q1, the Tellvest earnings-call sentiment score for Viatris (VTRS) is 8/10.
Viatris delivered strong Q1 revenue growth of $3.5B, representing operational growth of 3% year-over-year, with adjusted EPS of $0.59 as clean year-over-year comparisons (ex-Indore) finally showed the underlying business trajectory. FY2026 guidance was reaffirmed with potential to meet or exceed expectations, and Greater China growth accelerated to 18% while the enterprise strategic review delivered on track. The meloxicam NDA was accepted with a PDUFA date expected imminently, EFFEXOR GAD was approved in Japan, and selatogrel and cenerimod Phase 3 programs progressed alongside a CFO transition.
Scored from Viatris’s FY2026 Q1 earnings call. The newest quarter is available with Tellvest Pro.
Full Pro access for 30 days when you create a free account. No credit card required.
All prior quarters are free.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $3.53B | -8.1% | $-0.43 | +32.8% | 34.4% | -5.1% | -14.6% | $329M |
| FY2025 Q1 | $3.25B | -11.2% | $-2.55 | -2807.0% | 35.7% | -88.6% | -93.5% | $459M |
| FY2025 Q2 | $3.58B | -5.6% | $-0.00 | +98.6% | 37.2% | 6.5% | -0.1% | $166M |
| FY2025 Q3 | $3.76B | +0.2% | $-0.11 | -239.2% | 36.8% | 6.7% | -3.4% | $645M |
| FY2025 Q4 | $3.70B | +5.0% | $-0.30 | +30.2% | 30.6% | -7.2% | -9.2% | $551M |
| FY2026 Q1 | $3.52B | +8.1% | $0.15 | +105.9% | 32.9% | -2.3% | 5.0% | $348M |
| FY2026 Q2 | $3.76B | +4.9% | $-0.10 | — | 38.8% | 0.2% | -3.2% | $329M |